Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 3/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.53 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.53 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.53 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.53 |
| ▸ | GRIK4 | Q16099 | 2/20 | 0.53 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548054 | 1.00 | GRIN2D (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31378838 | 0.78 | DAO (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5795638 | 0.78 | DAO (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31378922 | 0.78 | DAO (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8222975 | 0.78 | GRIA1 (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7264691 | 0.78 | GRIA2 (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31378960 | 0.78 | DAO (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29381766 | 0.76 | MAPT (0.53) | CYP1A2MAPTCYP3A4HPGDBRD4 | |
| SCHEMBL375823 | 0.76 | MAPT (0.53) | CYP1A2MAPTCYP3A4HPGDBRD4 | |
| SCHEMBL5050400 | 0.75 | KDR (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| EP-0542609-A1 | 3-sulfonylamino-2-(1H)-quinolinones and 7-aza derivatives as excitatory amino acids antagonists | ADIR ET COMPAGNIE (FR) | 1993-05-19 | — | — | EP | claimed |
| US-12291502-B2 | Topoisomerase II-alpha inhibitors and methods of treating cancer using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-05-06 | — | — | US | disclosed |
| CN-119431239-A | Compounds, pharmaceutical compositions, kits and uses thereof | 密执安大学评议会 | 2025-02-14 | — | — | CN | disclosed |
| CN-113710241-B | Substituted bicyclic and tetracyclic quinones and related methods of use | 密执安大学评议会 | 2024-11-15 | — | — | CN | disclosed |
| EP-4427812-A2 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | The Regents of the University of Michigan (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-117186001-A | AHA1 inhibitor with multiple myeloma-resisting activity and preparation method and application thereof | 南京中医药大学 | 2023-12-08 | — | — | CN | disclosed |
| US-20230105776-A1 | Topoisomerase II-alpha Inhibitors and Methods of Treating Cancer Using the Same | UNITED STATES GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| EP-0933378-A1 | Quinolinone glycoside, production process, and anti-allergic agent | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1999-08-04 | — | — | EP | disclosed |
| EP-0885205-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5767130-A | Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists | OLNEY JOHN W (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1997031910-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| EP-0785190-A2 | Quinolinone derivative and antiallergic agent with said quinolinone derivative as the active ingredient | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996040141-A1 | 4,5-BRIDGED QUINOXALINEDIONES AND QUINOLONES AND THE USE THEREOF AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0542609-A1 | 3-sulfonylamino-2-(1H)-quinolinones and 7-aza derivatives as excitatory amino acids antagonists | ADIR ET COMPAGNIE (FR) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105776-A1 | Topoisomerase II-alpha Inhibitors and Methods of Treating Cancer Using the Same | TOP2A, TOP1, TOP2B | GRIN2D 4464/4885GRIN3B 3985/4885GRIN1 4134/4885 |
| US-12291502-B2 | Topoisomerase II-alpha inhibitors and methods of treating cancer using the same | TOP2A, TOP1, TOP2B | GRIN2D 4464/4885GRIN3B 3985/4885GRIN1 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.